Journal
CNS DRUGS
Volume 26, Issue 10, Pages 893-897Publisher
ADIS INT LTD
DOI: 10.2165/11209350-000000000-00000
Keywords
-
Categories
Ask authors/readers for more resources
Oromucosal midazolam (Buccolam (TM)), a benzodiazepine, is approved in the EU for the treatment of paediatric patients (aged 3 months to <18 years) with acute, prolonged, convulsive seizures. In clinical trials in children with prolonged, acute, convulsive seizures, oromucosal midazolam was at least as effective as rectal diazepam and as effective as intravenous diazepam in the treatment of seizures and was generally well tolerated. It has several advantages over rectal diazepam, the previous gold standard of treatment, such as having a more convenient and socially acceptable administration route.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available